Jounce Therapeutics Inc. (JNCE)

Market is closed

Hedge Fund Popularity

13F filing is ongoing

Hedge Fund Holdings
Filing Period:
Last update:
No. Hedge Fund Shares Value (x$1000) Activity % Port
1. 4,259,653 $12,907 0.84%
2.
Partner Fund Management

Christopher Medlock James

3,949,668 $11,967 -1% 0.45%
3.
OrbiMed Advisors

Samuel Isaly

2,928,900 $8,875 +3% 0.16%
4. 1,694,867 $5,136 -1% 0%
5.
Two Sigma Advisors

John Overdeck And David Siegel

320,500 $971 -2% 0%
Insider Trading: Purchases See All
Insider Price Amount Relationship Remaining Holdings Date Form 4
$7.84 1,900 Officer 1,900 2018-06-15 Filing
$16.00 5,000 Director 5,000 2017-02-01 Filing
$16.00 6,700 Director 27,025 2017-02-01 Filing
$16.00 625,000 Large Shareholder 3,456,463 2017-02-01 Filing
Insider Trading: Sales See All
Insider Price Amount Relationship Remaining Holdings Date Form 4
$6.65 5,378 Officer 85,202 2022-01-10 Filing
$7.30 3,005 Officer 90,580 2022-01-07 Filing
$6.65 23,924 Officer, Director 185,577 2022-01-10 Filing
$7.30 13,370 Officer, Director 209,501 2022-01-07 Filing
$6.65 8,222 Officer 52,614 2022-01-10 Filing
Institutional Investors' Holdings
Filing Period:
No. Name Shares Value (x$1000) % Port
1. 9,115 $27,618 0%
2. 4,358,433 $13,206 0.34%
3. 2,843,149 $8,615 0.83%
4. 2,664,323 $8,074 0%
5. 1,629,922 $4,937 0%
News See All